KYNTRA BIO, INC.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
KYNB$3.90+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Financial Statements and Supplementary Data
| Page | |
|---|---|
| FibroGen, Inc. | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | 85 |
| Financial Statements: | |
| Consolidated Balance Sheets | 87 |
| Consolidated Statements of Operations | 88 |
| Consolidated Statements of Comprehensive Loss | 89 |
| Consolidated Statements of Changes in Redeemable Non-controlling Interests and Stockholders’ Deficit | 90 |
| Consolidated Statements of Cash Flows | 91 |
| Notes to Consolidated Financial Statements | 92 |
| Financial Statement Schedule: | |
| II. Valuation and Qualifying Accounts for each of the two years ended December 31, 2024 | 136 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.